We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Immunomedics Inc in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 403 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 408 → 0 (-408)

100% less funds holding in top 10

Funds holding in top 10: 68 → 0 (-68)

100% less capital invested

Capital invested by funds: $17B → $0 (-$17B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 403

Holders
–
Holders Change
-408
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-68
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
403
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$2.23B
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.54B
3
BlackRock
BlackRock
New York
-$1.14B
4
HI
HBK Investments
Texas
-$553M
5
FCM
Farallon Capital Management
California
-$498M
Name Holding Trade Value Shares
Change 		Change in
Stake
SGCM
76
Sand Grove Capital Management
United Kingdom
– -$40M -470,000 Closed
TS
77
Twin Securities
New York
– -$39.8M -467,761 Closed
Two Sigma Investments
78
Two Sigma Investments
New York
– -$39.2M -461,415 Closed
Hudson Bay Capital Management
79
Hudson Bay Capital Management
Connecticut
– -$38.3M -450,000 Closed
Swiss National Bank
80
Swiss National Bank
Switzerland
– -$37.8M -444,850 Closed
GF
81
Gabelli Funds
New York
– -$37.7M -443,937 Closed
Bank of Nova Scotia
82
Bank of Nova Scotia
Ontario, Canada
– -$36.7M -431,684 Closed
AAMU
83
Amundi Asset Management US
Massachusetts
– -$33.7M -396,388 Closed
RA
84
Ramius Advisors
New York
– -$33.7M -395,947 Closed
MS
85
Maven Securities
Jersey
– -$32.8M -385,810 Closed
SFM
86
Soros Fund Management
New York
– -$32.7M -384,096 Closed
AA
87
AQR Arbitrage
Connecticut
– -$32.5M -382,284 Closed
UBS AM
88
UBS AM
Illinois
– -$31.6M -371,681 Closed
First Trust Advisors
89
First Trust Advisors
Illinois
– -$31.4M -368,852 Closed
WIC
90
Water Island Capital
New York
– -$31.3M -368,202 Closed
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
– -$30.9M -363,371 Closed
PP
92
Paloma Partners
Connecticut
– -$30.5M -358,288 Closed
Assenagon Asset Management
93
Assenagon Asset Management
Luxembourg
– -$30M -353,308 Closed
Alyeska Investment Group
94
Alyeska Investment Group
Illinois
– -$29.8M -350,000 Closed
SCC
95
Spring Creek Capital
Kansas
– -$28.9M -340,000 Closed
QOP
96
Quinn Opportunity Partners
Virginia
– -$27.4M -321,756 Closed
TEE
97
Tibra Equities Europe
United Kingdom
– -$27.1M -318,718 Closed
Man Group
98
Man Group
United Kingdom
– -$26.4M -310,752 Closed
GLAM
99
Gardner Lewis Asset Management
Pennsylvania
– -$26.1M -307,000 Closed
YCMGA
100
York Capital Management Global Advisors
New York
– -$25.7M -302,477 Closed
2 3
4
5 6

IMMU Hedge Fund Activity: Q4 2020 in Review

0 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q4 2020, worth a combined $0 — down 100% from $17B a quarter earlier.

Sellers outnumbered buyers: 403 funds closed out of IMMU and 0 opened new positions — a net loss of 403 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $2.23B sold.

  • 0 institutional investors held Immunomedics Inc (IMMU) as of Q4 2020, down from 408 in Q3 2020.
  • Funds reported $0 of Immunomedics Inc stock for Q4 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Immunomedics Inc positions in Q4 2020 and 403 closed out, a net change of -403 holders.
  • The largest Immunomedics Inc seller in Q4 2020 was Avoro Capital Advisors, an estimated $2.23B sold.

Based on aggregated 13F filings for Q4 2020.